The 5-year overall survival rate of patients with germ cell tumor (GCT) with poor prognosis, according to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification, is 48% after standard-dose chemotherapy and surgery, if necessary. Two recent studies have showed that early high-dose chemotherapy (HDCT) with hematopoietic progenitor cell support (HPCS) may induce a 2-year overall survival rate of 78% in these patients. We report the long-term results of the experience at the Department of Oncology in Ravenna with early HDCT and HPCS in GCT patients with poor prognosis (IGCCCG criteria). Between 1987 and 2002, 18 poor prognosis GCT patients (17 M, one F), median age 24.5 years (range, 17-52), were treated with early HDCT with HPCS. In total, (67%) patients achieved a complete remission and they are continuously disease-free at a median follow-up of 9.2 years (range, 1.7-16.2). One treatment-related death occurred. No patient developed myelodysplasia or a secondary leukemia. This is notably the longest follow-up reported in patients having received HDCT in this setting. No patient achieving a complete remission relapsed. The role of HDCT in poor prognosis GCT will be defined from the ongoing phase III randomized trials. Conventional treatment for patients with advanced germ cell tumor (GCT), consisting of a chemotherapy regimen with cisplatin, etoposide, and bleomycin (PEB), with or without surgical resection of residual disease, is curative in nearly 80% of patients, while approximately 25% of relapsed patients may be cured by a standard-dose cisplatin plus ifosfamide-based regimen.
chemotherapy; hematopoietic progenitor cell support Conventional treatment for patients with advanced germ cell tumor (GCT), consisting of a chemotherapy regimen with cisplatin, etoposide, and bleomycin (PEB), with or without surgical resection of residual disease, is curative in nearly 80% of patients, while approximately 25% of relapsed patients may be cured by a standard-dose cisplatin plus ifosfamide-based regimen. [1] [2] [3] Various prognostic classifications based on clinical parameters have been developed in patients with advanced GCT. [4] [5] [6] In 1997, these classifications were replaced by the staging system for advanced disease of the International Germ Cell Cancer Collaborative Group (IGCCCG), which allowed careful stratification in patients with good, intermediate, and poor prognosis. 7 The last group includes nonseminomatous GCT patients with any of mediastinal primary tumor or nonpulmonary visceral metastases or any of beta-human chorionic gonadotropin (bHCG) 450 000 IU/l or alphafetoprotein (AFP) 410 000 ng/ml or lactate dehydrogenase (LDH) 410 Â upper limit of normal. For these patients, the 5-year survival rate is 48%, ranging between 42 and 54%, after conventional-dose cisplatin-based chemotherapy and surgery, if necessary. 7, 8 So far, several attempts have been made to improve the outcome of patients with poor prognosis GCT, including the use of cisplatinintensified regimens and alternating chemotherapy sequences. [9] [10] [11] In addition, high-dose chemotherapy (HDCT) with hematopoietic progenitor cell support (HPCS), initially studied in relapsed or refractory GCT, has been investigated as a part of the first-line treatment of patients presenting with poor prognosis disease. 12 Since 1987, at the Department of Oncology in Ravenna, we have adopted the policy to intensify the response with one or two courses of HDCT with HPCS in poor prognosis GCT patients with chemosensitive disease.
We retrospectively reviewed our own experience of early HDCT with HPCS in patients with poor prognosis GCT, reclassified according to the IGCCCG classification, and analyzed long-term survival and morbidity data.
Patients and methods

Patients
Between 1987 and 2002, at the Department of Oncology in Ravenna, 18 GCT patients (17 M, one F), median age 24. 5 years (range, 17-52), underwent 25 courses of HDCT programs with HPCS. In total, 16 male patients achieved a partial remission after standard-dose induction chemotherapy. Another one with mediastinal disease achieved a complete remission. The female patient, who presented extragonadal GCT of unknown primary site with liver metastases and AFP ¼ 216 000 ng/mL, achieved a complete remission with standard-dose induction chemotherapy, and was included in this analysis. All patients presented poor prognosis disease in accordance with IGCCCG criteria. 7 Patient characteristics before induction chemotherapy are listed in Table 1 . The evaluation before treatment in all patients included the following: history and physical examination, screening chemistry profile, determination of serum levels of the tumor markers bHCG, AFP, and LDH, electrocardiogram, and computerized tomography scan of the chest, abdomen, and pelvis. Patients were required to have a Karnofsky performance status of at least 60%, and no major organ dysfunction.
Before 1997, patients were categorized as poor prognosis using the Indiana Staging System. 5 With the development of the IGCCCG classification in 1997, this has been used to reclassify patients treated before this date and has been prospectively used since. 7 
Treatment
The conventional-dose induction regimens prior to HDCT were PEB in 15 patients, etoposide, ifosfamide, cisplatin (VIP) in two, and PEB alternated with cisplatin, vincristine, methotrexate, and bleomycin (POMB) in one case. Treatment cycles were repeated every 3 weeks. The median number of induction treatment cycles was 4 (range, [3] [4] [5] of etoposide, and 6400 mg/m 2 of cyclophosphamide (CEC) in eight courses. In total, 18 courses were supported by autologous bone marrow transplantation, six by peripheral blood stem cells (PBSCs), and one by both of them.
Mobilizing courses for PBSC collection were as follows: VeIP (vinblastine 0.22 mg/kg, ifosfamide 6 g/m 2 , and cisplatin 100 mg/m 2 ) plus filgrastim 5 mg/kg/day in two patients, PE (cisplatin 100 mg/m 2 , etoposide 500 mg/m 2 ) plus molgramostim 5 mg/kg/day in one patient, cyclophosphamide 7 g/m 2 plus filgrastim 5 mg/kg/day in one case, filgrastim 10 mg/kg/day only in two cases. 13 Definitions and evaluation of toxicity, response, and survival A clinical complete response (cCR) to chemotherapy was defined as the disappearance of all clinical, radiographic, and biochemical evidence of disease for at least 4 weeks (cCR). A pathological complete response (pCR) included patients in whom surgical resection of residuum yielded necrosis, fibrosis, or mature teratoma without evidence of viable malignant cells. A complete response to chemotherapy plus surgery (sCR) was defined as the complete excision of all masses, at least one of which contained viable GCT other than mature teratoma. Partial response with negative markers (PRmÀ) was defined as more than 50% reduction in bidimensional tumor measurements with normalization of all prior elevated tumor markers. Partial response with positive tumor markers (PRm þ ) was defined as more than a 50% reduction in bidimensional tumor measurements without normalization of all prior elevated tumor markers. Stable disease (SD) was considered as a less than 50% 14 The overall and disease-free survival rates were calculated from the start of induction chemotherapy to the date of the last follow-up evaluation or death, and the date of relapse, respectively.
Results
Toxicity
One patient died of acute respiratory distress syndrome 3 weeks after the administration of HDCT. In all patients, a median of 1.3 Â 10 8 /kg (range, 0.3-7.3) MNC per course was reinfused. The median time to the recovery of absolute neutrophil count (ANC) higher than 500/ml and platelet count over 20 000/ml was 11 (range, 7-21) and 8 (range, 1-22) days, respectively. The median number of platelet and red cell transfusions per course was 4 (range, 1-10) and 6 (range, 2-14), respectively. The median duration of fever was 5 days (range, 0-10), and clinically documented infections occurred in 17 (68%) courses. The median duration of hospitalization was 29 days (range, 22-41). The following nonhematological side effects were the most relevant: grade 43 abdominal pain (seven courses), grade 43 vomiting (seven courses), grade 43 stomatitis (six courses), grade 3 hepatic toxicity (one course), grade 3 diarrhea (one course). Neither renal and cardiac toxicities, nor engraftment syndrome were observed.
Response and long-term survival
Overall, eight patients achieved a pCR, four patients cCR, one patient PRm þ , three patients SD, one patient PD, and one patient died of treatment-related toxicity. Of 12 (67%) patients achieving pCR and cCR, none relapsed with a median follow-up of 111 months (range, 20-194 months). Of five patients with persistent disease after HDCT, four underwent further chemotherapeutic treatments without any response. Thus, with early HDCT, 12 patients (67%) are continuously disease-free. The results are presented in detail in Table 2 .
Late toxicities
No patient developed myelodysplasia or a secondary leukemia. Among the 12 long-term survivors, the most important sequalae after HDCT were grade 2 high-tone hearing impairment in one case and grade 1 peripheral nervous system toxicities with paresthesias of the hands and feet in three patients. No patient had cardiac or renal failure.
Discussion
In the last few years, HDCT with HPCS has been increasingly investigated as a therapeutic option for patients with relapsed or refractory GCT and as a first-line Table 2 Early HDCT for poor prognosis germ cell tumor treatment for patients with poor prognosis GCT. The first experiments with early HDCT in patients with poor prognosis GCT were performed at the Memorial Sloan Kettering Cancer Center. A significantly improved overall and disease-free survival was observed for patients treated with HDCT compared with prior studies, based on standard-dose chemotherapy. 15 Two phase II studies have recently determined the efficacy of one or more courses of HDCT as intensification after one or more courses of standard-dose induction chemotherapy for poor prognosis GCT patients, as strictly defined by the IGCCCG criteria. [16] [17] [18] Bokemeyer et al employed one course of standard-dose VIP followed by 3-4 courses of high-dose VIP supported by PBSCs. The overall and event-free survival rates at 2 years were 78 and 73%, respectively. 16 In all, 22 patients with metastatic GCTs, including brain metastases at the time of initial diagnosis, were identified within this HDCT study group. In total, 17 (77%) patients are continuously disease-free at a median follow-up of 23 months. 17 Decatris et al reported the results of a series of 20 GCT patients treated with three or four courses of PEB followed by HDCT (CEC) with PBSC support. The 2-year overall survival rate was 78%, while the 4-year overall survival rate was 66%. 18 In our experience with chemotherapeutic regimens including one or two courses of early HDCT after induction chemotherapy, 12 (67%) patients achieved a CR and they are continuously disease-free at a median follow-up of 9.2 years (range, 1.7-16.2). Interestingly, of 12 patients achieving a CR after HDCT no patient relapsed, while the five patients, achieving one PRm þ , three SD and one PD, died within 16 months. All of the nine patients who achieved either a PRmÀ or CR after induction chemotherapy went on to CR after HDCT. Instead, among the remaining nine patients achieving only a PRm þ after induction chemotherapy, the CR rate after HDCT was only 33% (three of nine patients). In patients who achieve only a PRm þ after conventional therapy, some authors consider HDCT as initial salvage, rather than late intensification of initial therapy. 19 We included a female patient with GCT with poor prognosis features (extragonadal GCT with liver metastases and a very high AFP level). Other studies with HDCT in GCT patients have associated male and female patients. [20] [21] [22] The results with chemotherapy in advanced ovarian GCT are generally good, but probably less than male GCT with similar clinical features. 23 In the current report, one toxic death occurred in 18 GCT patients treated with early HDCT. No patient developed myelodysplasia or secondary leukemia after HDCT, even though an increased incidence was reported in the major studies. 24, 25 The incidence of late symptomatic neurotoxicity and ototoxicity is comparable to the reported frequencies in previous studies with standard-dose chemotherapy, while no patient presented cardiac or renal failure. 26 The results of our experience are comparable to those reported in other studies with early HDCT in GCT patients with poor prognosis disease, as defined by the IGCCCG criteria, but for the first time we confirmed the outcome of these patients at long-term follow-up. [16] [17] [18] However, despite the favorable results of these studies, the only randomized trial published so far, comparing HDCT (high-dose cisplatin, etoposide, cyclophosphamide) as late intensification after three courses of cisplatin, vinblastine, etoposide, and bleomycin (PVeEB) with four courses of PVeEB, showed no benefit for the HDCT arm. However, this study presented a number of relevant limitations: only 114 randomized patients, PVeEB cannot be considered a standard treatment, the dose-intensity in the HDCT arm was low, and nearly 30% of the patients initially randomized to the HDCT arm did not complete the treatment because of early death or toxicity. 27 Instead, the results of a matched-pair analysis indicate that first-line HDCT (high-dose cisplatin, etoposide, and ifosfamide) may induce a statistically significant improvement of the estimated 2-year disease-free survival ( þ 16%, P ¼ .0056) and estimated 2-year overall survival ( þ 11%, P ¼ .0184), as compared with standard chemotherapy (PEB or VIP). 28 Three phase III randomized studies are ongoing. A US Intergroup phase III randomized trial compares four courses of PEB with two courses of PEB followed by two courses of HDCT (CEC) supported by hematopoietic stem cells. The European Organization for Research and Treatment of Cancer (EORTC) conducted a phase III randomized study comparing four courses of PEB with one course of standard-dose VIP followed by three courses of high-dose VIP and hematopoietic stem cell rescue. An Italian phase III randomized study comparing four courses of PEB with two courses of PEB followed by high-dose sequential (HDS) consisting of one course of high-dose cyclophosphamide, two cycles of a super-PEB (containing high-dose etoposide), and one final course of high-dose carboplatin.
In our experience, early HDCT induced impressive long-term disease-free survival in poor prognosis GCT patients. The final results of the three ongoing phase III randomized trials are needed to define the role of HDCT as a part of the initial management of poor prognosis GCT patients.
